The US FDA Grants Fast Track Designation to RemeGen's RC88 for Ovarian Cancer
Shots:
- Following the IND approval in the Dec’23, the company’s RC88 has received FTD from the US FDA for treating Pt-resistant recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancers
- The company’s RC88 is being evaluated as monotx. for its optimal dosage, effectiveness, and safety in P-II trial to treat Pt-resistant recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancers
- RC88, recombinant humanized anti-MSLN mAb associated with the microtubule inhibitor monomethyl auristatin E (MMAE), binds to tissues overexpressing MSLN, demonstrating a terminating effect on tumor cells with varying MSLN expression levels
Ref: PRNewswire | Image: RemeGen
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
